JP2005532315A - メチル化免疫刺激性オリゴヌクレオチド及びその使用方法 - Google Patents

メチル化免疫刺激性オリゴヌクレオチド及びその使用方法 Download PDF

Info

Publication number
JP2005532315A
JP2005532315A JP2004503046A JP2004503046A JP2005532315A JP 2005532315 A JP2005532315 A JP 2005532315A JP 2004503046 A JP2004503046 A JP 2004503046A JP 2004503046 A JP2004503046 A JP 2004503046A JP 2005532315 A JP2005532315 A JP 2005532315A
Authority
JP
Japan
Prior art keywords
methylated
lipid
antigen
nucleic acid
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004503046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532315A5 (enExample
Inventor
ケー． タム，イン
センプル，ショーン
クリマック，サンドラ
チク，ガニア
Original Assignee
イネックス ファーマシューティカルズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/290,545 external-priority patent/US20030125292A1/en
Application filed by イネックス ファーマシューティカルズ コーポレイション filed Critical イネックス ファーマシューティカルズ コーポレイション
Publication of JP2005532315A publication Critical patent/JP2005532315A/ja
Publication of JP2005532315A5 publication Critical patent/JP2005532315A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2004503046A 2002-05-10 2003-05-12 メチル化免疫刺激性オリゴヌクレオチド及びその使用方法 Pending JP2005532315A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37934302P 2002-05-10 2002-05-10
US10/290,545 US20030125292A1 (en) 2001-11-07 2002-11-07 Mucoscal vaccine and methods for using the same
US46064603P 2003-04-04 2003-04-04
PCT/CA2003/000678 WO2003094963A2 (en) 2002-05-10 2003-05-12 Methylated immunostimulatory oligonucleotides and methods of using the same

Publications (2)

Publication Number Publication Date
JP2005532315A true JP2005532315A (ja) 2005-10-27
JP2005532315A5 JP2005532315A5 (enExample) 2006-06-29

Family

ID=29424457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004503046A Pending JP2005532315A (ja) 2002-05-10 2003-05-12 メチル化免疫刺激性オリゴヌクレオチド及びその使用方法
JP2004502917A Pending JP2005530761A (ja) 2002-05-10 2003-05-12 癌ワクチン及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004502917A Pending JP2005530761A (ja) 2002-05-10 2003-05-12 癌ワクチン及びその使用方法

Country Status (10)

Country Link
EP (2) EP1503793A2 (enExample)
JP (2) JP2005532315A (enExample)
CN (1) CN1665531A (enExample)
AT (1) ATE411815T1 (enExample)
AU (2) AU2003229433B2 (enExample)
CA (2) CA2484266A1 (enExample)
DE (1) DE60324270D1 (enExample)
IL (1) IL165107A0 (enExample)
MX (1) MXPA04011127A (enExample)
WO (2) WO2003094828A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011037262A1 (ja) * 2009-09-28 2011-03-31 シスメックス株式会社 抗メチル化ｄｎａ抗体を産生するハイブリドーマおよびその利用
JP2023533871A (ja) * 2020-07-14 2023-08-04 エヴァクシオン・バイオテック・アクティエセルスカブ 免疫療法のためのａｐｃ標的化単位

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EA008777B1 (ru) 2002-10-29 2007-08-31 Коли Фармасьютикал Груп, Лтд. Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
CN102203618B (zh) 2008-10-30 2014-10-15 郭培宣 用于dna测序和其他用途的膜集成病毒dna包装马达蛋白连接器生物传感器
CN109985234A (zh) * 2019-04-12 2019-07-09 南华大学 一种梅毒螺旋体dna疫苗及其应用
CN116602920B (zh) * 2023-04-18 2024-03-19 中国科学技术大学 一种透皮肽修饰、含有Ce6和CpG的脂质体及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3468773B2 (ja) * 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
FI107974B (fi) * 1999-07-14 2001-10-31 Nokia Networks Oy Menetelmä ja järjestelmä tilastointiin puhelinkeskusjärjestelmässä
DE60036950T2 (de) * 1999-08-27 2008-08-07 Inex Pharmaceuticals Corp., Burnaby Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
JP2005516897A (ja) * 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011037262A1 (ja) * 2009-09-28 2011-03-31 シスメックス株式会社 抗メチル化ｄｎａ抗体を産生するハイブリドーマおよびその利用
US9169330B2 (en) 2009-09-28 2015-10-27 Sysmex Corporation Hybridoma producing anti-methylated DNA antibody and utilization of same
JP2023533871A (ja) * 2020-07-14 2023-08-04 エヴァクシオン・バイオテック・アクティエセルスカブ 免疫療法のためのａｐｃ標的化単位

Also Published As

Publication number Publication date
CA2485400A1 (en) 2003-11-20
WO2003094828A3 (en) 2004-02-05
CA2484266A1 (en) 2003-11-20
EP1506010A2 (en) 2005-02-16
WO2003094828A2 (en) 2003-11-20
AU2003229434A1 (en) 2003-11-11
EP1503793A2 (en) 2005-02-09
EP1506010B1 (en) 2008-10-22
AU2003229433A1 (en) 2003-11-11
AU2003229433B2 (en) 2008-04-24
WO2003094963A2 (en) 2003-11-20
JP2005530761A (ja) 2005-10-13
MXPA04011127A (es) 2005-07-01
AU2003229434A8 (en) 2003-11-11
CN1665531A (zh) 2005-09-07
ATE411815T1 (de) 2008-11-15
DE60324270D1 (de) 2008-12-04
WO2003094963A3 (en) 2004-02-12
IL165107A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
US20040009943A1 (en) Pathogen vaccines and methods for using the same
JP2007509040A (ja) 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
AU2002340662B2 (en) Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
de Jong et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN
JP5016733B2 (ja) 免疫賦活性オリゴヌクレオチド
KR100737980B1 (ko) 사이토카인 분비 자극용 및 면역반응 유도용 조성물
CN101874112B (zh) 特别是作为免疫刺激剂/佐剂的式(I)：GlXmGn或式(II)：ClXmCn的核酸
TWI558412B (zh) 包含陽離子性脂質之組合物及其用途
AU2003229433B2 (en) Methylated immunostimulatory oligonucleotides and methods of using the same
AU2002340662A1 (en) Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
JP2011518170A (ja) カチオン性脂質の鏡像異性体による免疫応答の刺激
Akache et al. Adjuvants: Engineering protective immune responses in human and veterinary vaccines
US20040013649A1 (en) Cancer vaccines and methods of using the same
US20040009944A1 (en) Methylated immunostimulatory oligonucleotides and methods of using the same
CA3022924A1 (en) Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
EP1505942B1 (en) Pathogen vaccines and methods for using the same
US20220370490A1 (en) Synergistic immunostimulation through the dual activation of tlr3/9 with spherical nucleic acids
WO2022034555A1 (en) Polynucleotide constructs and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090811

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100302